Biopharmaceutical company Dizal (SSE:688192) announced on Friday that it has submitted a New Drug Application (NDA) to the US FDA for sunvozertinib, targeting locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (exon20ins) post-platinum-based chemotherapy.
Data from the pivotal WU-KONG1 Part B study, featured at the 2024 ASCO Annual Meeting, supports the application, highlighting significant objective response rates and a manageable safety profile.
Sunvozertinib, an oral EGFR inhibitor, previously received accelerated approval in China and Breakthrough Therapy Designations from both the US FDA and China CDE. Demonstrating efficacy across various EGFR exon20ins subtypes and brain metastasis cases, the drug addresses a key unmet need, improving outcomes for patients with poorer prognosis.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval